CERO THERAPEUTICS HOLDINGS, INC. (CERO)
2025-06-30 | ||||
|---|---|---|---|---|
| Deemed dividend on series a, b and c preferred stock | 24,700,374 | |||
| Research and development | 2,753,963 | |||
| General and administrative | 1,969,828 | |||
| Total operating expenses | 4,723,791 | |||
| Loss from operations | -4,723,791 | |||
| Other expenses | - | |||
| Interest income (expense), net | 13,776 | |||
| Change in fair value of earnout and derivative liabilities | - | |||
| Stock-based inducement expense | 707,300 | |||
| Gain from settlement of liabilities with vendors | - | |||
| Total other income (expenses), net | -693,524 | |||
| Net loss | -5,417,315 | |||
| Deemed dividend related to series c common warrants | - | |||
| Net loss attributable to common shareholders | -30,117,689 | |||
| Basic (in dollars per share) | -61.71 | |||
| Basic (in shares) | 488,076 | |||
| Diluted (in dollars per share) | -61.71 | |||
| Diluted (in shares) | 488,076 | |||